These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 38167622)

  • 1. Immunohistochemical FAP Expression Reflects
    Spektor AM; Gutjahr E; Lang M; Glatting FM; Hackert T; Pausch T; Tjaden C; Schreckenberger M; Haberkorn U; Röhrich M
    J Nucl Med; 2024 Jan; 65(1):52-58. PubMed ID: 38167622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Static and Dynamic
    Lang M; Spektor AM; Hielscher T; Hoppner J; Glatting FM; Bicu F; Hackert T; Heger U; Pausch T; Gutjahr E; Rathke H; Giesel FL; Kratochwil C; Tjaden C; Haberkorn U; Röhrich M
    J Nucl Med; 2023 Feb; 64(2):244-251. PubMed ID: 35906094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of preoperative [
    Ding J; Qiu J; Hao Z; Huang H; Liu Q; Liu W; Ren C; Hacker M; Zhang T; Wu W; Huo L; Li X
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1780-1791. PubMed ID: 36695823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased SOX9 Expression in Premalignant and Malignant Pancreatic Neoplasms.
    Gnerlich JL; Ding X; Joyce C; Turner K; Johnson CD; Chen H; Abood GJ; Pappas SG; Aranha GV
    Ann Surg Oncol; 2019 Feb; 26(2):628-634. PubMed ID: 30357576
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Kessler L; Hirmas N; Pabst KM; Hamacher R; Ferdinandus J; Schaarschmidt BM; Milosevic A; Nader M; Umutlu L; Uhl W; Reinacher-Schick A; Lugnier C; Witte D; Niedergethmann M; Herrmann K; Fendler WP; Siveke JT
    J Nucl Med; 2023 Dec; 64(12):1910-1917. PubMed ID: 37973185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of
    Röhrich M; Naumann P; Giesel FL; Choyke PL; Staudinger F; Wefers A; Liew DP; Kratochwil C; Rathke H; Liermann J; Herfarth K; Jäger D; Debus J; Haberkorn U; Lang M; Koerber SA
    J Nucl Med; 2021 Jun; 62(6):779-786. PubMed ID: 33097632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception.
    Hernandez S; Parra ER; Uraoka N; Tang X; Shen Y; Qiao W; Jiang M; Zhang S; Mino B; Lu W; Pandurengan R; Haymaker C; Affolter K; Scaife CL; Yip-Schneider M; Schmidt CM; Firpo MA; Mulvihill SJ; Koay EJ; Wang H; Wistuba II; Maitra A; Solis LM; Sen S
    Clin Cancer Res; 2022 May; 28(9):1938-1947. PubMed ID: 35491652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A rare case of intraductal tumor of the pancreas in which an intraductal tubulopapillary neoplasm was mixed with a widely spreading gastric-type intraductal papillary-mucinous neoplasm].
    Wakabayashi T; Shirota Y; Takeda Y; Hodo Y; Ueda Y
    Nihon Shokakibyo Gakkai Zasshi; 2024; 121(5):415-424. PubMed ID: 38735750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk.
    Fritz S; Klauss M; Bergmann F; Strobel O; Schneider L; Werner J; Hackert T; Büchler MW
    Ann Surg; 2014 Nov; 260(5):848-55; discussion 855-6. PubMed ID: 25379856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [
    Zhu Z; Cheng K; Yun Z; Zhang X; Hu X; Liu J; Wang F; Fu Z; Yue J
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3425-3438. PubMed ID: 37328622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of early and late
    Hoppner J; van Genabith L; Hielscher T; Heger U; Sperling L; Colbatzky T; Gutjahr E; Lang M; Pausch T; Spektor AM; Glatting FM; Liermann J; Hackert T; Kratochwil C; Giesel FL; Haberkorn U; Röhrich M
    Sci Rep; 2023 Oct; 13(1):17848. PubMed ID: 37857656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic ductal adenocarcinomas associated with intraductal papillary mucinous neoplasms (IPMNs) versus pseudo-IPMNs: relative frequency, clinicopathologic characteristics and differential diagnosis.
    Muraki T; Jang KT; Reid MD; Pehlivanoglu B; Memis B; Basturk O; Mittal P; Kooby D; Maithel SK; Sarmiento JM; Christians K; Tsai S; Evans D; Adsay V
    Mod Pathol; 2022 Jan; 35(1):96-105. PubMed ID: 34518632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
    Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
    Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the clinical value of baseline [
    Ding J; Qiu J; Hao Z; Huang H; Liu Q; Liu W; Ren C; Hacker M; Zhang T; Wu W; Li X; Huo L
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4036-4050. PubMed ID: 37493664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative imaging to evaluate malignant potential of IPMNs.
    Hanania AN; Bantis LE; Feng Z; Wang H; Tamm EP; Katz MH; Maitra A; Koay EJ
    Oncotarget; 2016 Dec; 7(52):85776-85784. PubMed ID: 27588410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of positron emission tomography (PET)/contrast-enhanced computed tomography (CE-CT) in discriminating between malignant and benign intraductal papillary mucinous neoplasms (IPMNs).
    Ohta K; Tanada M; Sugawara Y; Teramoto N; Iguchi H
    Pancreatology; 2017; 17(6):911-919. PubMed ID: 29033011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Risk of Malignancy in Branch-Duct Intraductal Papillary Mucinous Neoplasms.
    Oyama H; Tada M; Takagi K; Tateishi K; Hamada T; Nakai Y; Hakuta R; Ijichi H; Ishigaki K; Kanai S; Kogure H; Mizuno S; Saito K; Saito T; Sato T; Suzuki T; Takahara N; Morishita Y; Arita J; Hasegawa K; Tanaka M; Fukayama M; Koike K
    Gastroenterology; 2020 Jan; 158(1):226-237.e5. PubMed ID: 31473224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.